Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.